UBS downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $11, down from $26. The firm says the company’s “multiple” research and development and regulatory setbacks have lowered confidence on the viability of its remaining pipeline programs. Most of the immediate value in Biohaven’s pipeline comes from Kv7, but the company is two years behind competitor Xenon in the primary indication, the analyst tells investors in a research note. UBS sees a balanced risk/reward for the shares into the upcoming pipeline catalysts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
- Biohaven price target lowered to $15 from $47 at JPMorgan
- Biohaven call volume above normal and directionally bullish
- Biohaven price target lowered to $26 from $54 at Morgan Stanley
- Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges